Support for transferring cell line and upstream CMC process knowledge between development teams, sites, partners, CDMOs and manufacturing organisations. A process is only transferred when the receiving site can reproduce it – not when the documents arrive.
Our transfer process
01
Assess
Critical process and product knowledge, development gaps, scale and comparability risks.
02
Package
Scientifically robust CMC and process-transfer documents.
03
Transfer
Scientific support and troubleshooting during transfer execution.
04
Ready
Comparability confirmed and handover towards manufacturing.
Most delays happen when a bench process meets a large bioreactor
A biologic passes through three or four transfers in its life – from 10 mL–10 L process development, to 50–200 L pilot/tox, 500–2,000 L clinical GMP and 2,000 L+ commercial scale.1 Most delays occur at the first step.2
$80M
lost for each month of transfer delay on a biologic selling $1B a year2
6–12 months
launch delay from one missed gap in equipment, raw materials or an analytical method3
$100K+
to rerun one failed 2,000-litre batch2
Where and how an asset is made is now part of what it is worth. With the US BIOSECURE Act signed in December 2025, sponsors are seeking capacity in the US, Europe, South Korea and India – and buyers increasingly ask whether a process can move sites.4,5
Where rushed timelines break
Receiving-site equipment differs from the sending site; few programmes compare sites or build a scale-down model before GMP.6
Where Z2 helps
Site gap analysis, a transfer protocol, engineering runs and a comparability plan.
Sources
- L7 Informatics. Top 5 reasons tech transfer keeps breaking, May 2025. L7 Informatics
- BioPharm International. Current challenges with cell culture scale-up for biologics production (citing Matzmorr). BioPharm International
- BioProcess Tools. Technology transfer for biologics manufacturing, June 2026 (practitioner estimate). BioProcess Tools
- BIOSECURE Act: Arnold & Porter, Dec 2025; FDA Law Blog, Jun 2026; Zenas BioPharma 10-K FY2025. Arnold & Porter FDA Law Blog
- Vision Life Sciences. CDMO market analysis 2026, Feb 2026. Vision Life Sciences
- BioProcess Online. 9 common tech transfer pitfalls to avoid. BioProcess Online
